IL-6, an activator of STAT3, frequently elevated in RCC [31], is known to induce tumor progression and metastasis across tumor types [43], and is sufficient to induce skeletal muscle STAT3 activation leading to muscle wasting resulting cachexia [44,45]. This evidence concerns the gene IL6 and renal cell carcinoma.